Technology Transfer Tactics will be offering a webinar providing "Expert Analysis of Federal Circuit's Ruling in Myriad Appeal" on August 31, 2011 from 1:00 - 2:00 PM (Eastern). Patent Docs author Dr. Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff LLP will discuss the Federal Circuit's "fractured" decision in the AMP v. USPTO ("Myriad") case, and what it means for technology transfer offices and university researchers with gene-based innovations, in terms of both patenting and licensing. In particular, the webinar will cover:
• Patentability of composition of matter claims (where the Federal Circuit reversed the District Court's finding that "isolated DNA" was not patent-eligible under the "products of nature" exception);
• Impact on method claims -- both diagnostic methods and screening method claims;
• The decision's creation of a new categorical rule of patent-ineligibility;
• Rejection of the "magic microscope" analysis by the government;
• Likely outcome of future appeals;
• Impact on patent prosecution decisions and claim drafting; and
• "Isolation" vs. "purification" -- what’s the difference?
The registration fee for the webinar is $197 ($247 for registration plus CLE processing). Those interested in registering for the webinar, can do so here.
Comments